CVRx, Inc. is a commercial-stage medical device company. The Company is focused on developing, manufacturing and commercializing advanced neuromodulation solutions for patients with cardiovascular diseases. The Company's integrated platform technology, Barostim, is designed to leverage the power of the brain and nervous system to address the imbalance of the autonomic nervous system (ANS), which causes heart failure with reduced ejection fraction (HFrEF) and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy (BAT) by sending imperceptible and persistent electrical pulses to baroreceptors located in the wall of the carotid artery to signal the brain to modulate cardiovascular function. Barostim is a minimally invasive neuromodulation device that consists of two implantable components, an implantable pulse generator (IPG) and a stimulation lead, and is programed by a wireless clinician-controlled programmer that communicates with the IPG.
BörsenkürzelCVRX
Name des UnternehmensCVRx Inc
IPO-datumJun 30, 2021
CEOMr. Kevin Hykes
Anzahl der mitarbeiter206
WertpapierartOrdinary Share
GeschäftsjahresendeJun 30
Addresse9201 West Broadway Avenue
StadtMINNEAPOLIS
BörseNASDAQ Global Select Consolidated
LandUnited States of America
Postleitzahl55445
Telefon17634162850
Websitehttps://www.cvrx.com/
BörsenkürzelCVRX
IPO-datumJun 30, 2021
CEOMr. Kevin Hykes
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten